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Abstract
Background: Visceral Leishmaniasis coinfection with HIV/AIDS has emerged as a series of disease pattern. It most
often results in unfavorable responses to treatment, frequent relapses, and deaths. Scarce data is available regarding
the prevalence of HIV and associated factors among Visceral Leishmaniasis coinfected patients. This study sought to
determine the prevalence of HIV and associated factors among Visceral Leishmaniasis infected patients.
Methods: Facility based cross-sectional study was conducted from October, 2015 to August, 2016 in Northwest
Ethiopia. Cluster sampling technique was used to select 462 Visceral Leishmaniasis infected patients. Serologic and
parasitological test results have been used to diagnose Visceral Leishmaniasis. The HIV diagnosis was based on the
national algorithm with two serial positive rapid test results. In case of discrepancy between the two tests, Uni-Gold
TM was used as a tie breaker. Structured questionnaire was used to collect independent variables. Data was entered
by using Excel and analyzed by using SPSS version 20. Descriptive statistics and logistic regression model was used
to analyze the data.
Results: A total of 462 study participants were included in the study with a response rate of 92.4%. HIV and Visceral
Leishmaniasis coinfection was found to be 17.75% with 95% CI; 14.30–21.40. Age≥ 30 years (AOR = 22.58, 95% CI 11.34,
45.01), urban residents (AOR = 2.02, 95% CI 1.16, 4.17) and daily laborer workers (AOR = 4.99, 95% CI 2.33, 10.68) were
significantly associated with HIV and Visceral Leishmaniasis coinfection.
Conclusion: HIV and Visceral Leishmaniasis coinfection in the Northwest Ethiopia was found to be low. Age, residence
and employment were independently associated with HIV-VL coinfection in the Northwest Ethiopia. It is better to
design interventions to prevent and control HIV-VL coinfection for productive age groups (age≥ 30) and daily laborers.
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Background
Visceral Leishmaniasis (VL; also known as “kala-azar”)
is a systemic parasitic disease caused by the parasite
Leishmania donovani species complex. It is estimated
about 500,000 new cases of VL occur annually world-
wide [1]. VL is characterized by irregular bouts of
fever, substantial weight loss, swelling of the spleen
and liver, and anemia (which may be serious). If the
disease is not treated, the fatality rate in developing coun-
tries can be as high as 100% within 2 years [2]. VL acceler-
ates HIV replication and disease progression, mainly by
chronic immune stimulation [3].
The prevalence of patients with both HIV and VL in-
fection (hereafter, “HIV-VL coinfection”) in Europe has
fallen sharply since 1996, when antiretroviral treatment
(ART) became standard [4, 5]. In India and particularly
in Africa, HIV-VL coinfection is emerging [4, 5]. The
AIDS pandemic has expanded to rural areas where VL is
endemic, with cases of HIV-VL coinfection reported in
35 countries [4, 5], among which Ethiopia carries the
greatest burden. The affected populations are mainly
very poor male seasonal migrant workers that travel in
the harvesting season from non endemic highlands to
the cotton, sesame and sorghum fields of Humara and
Metama, the VL endemic low lands situated on the
Sudanese boarders [6, 7].
In Ethiopia, HIV prevalence has declined from 1.5% in
2011 to 1.1% in 2015 [8]. Hence, in spite of the decreas-
ing prevalence of HIV in the general population, the
prevalence of HIV among VL patients has remained pro-
portionally very high. The prevalence of HIV-VL coin-
fection from different studies in Ethiopia range from
18.1 to 48.5% [9, 10]. The real burden is likely to be
underestimated or overestimated because of rapid de-
crease of HIV infection in Ethiopia [8]. There is however
knowledge gap on the current prevalence of HIV among
VL infected patients.
In most of the studies done outside Ethiopia, fac-
tors associated with HIV-VL coinfection were ad-
vanced HIV-1 disease [11, 12], intravenous drug users
[11, 13], CDC clinical category C [14, 15] and CD4
cell count below 300 cells/mm3 [15]. Nevertheless,
one hospital based case series study done in Ethiopia
showed that age was significantly associated with
HIV-VL coinfection [16]. Therefore, there is a scarcity
of data on factors associated with HIV-VL coinfected
patients in Ethiopian context.
This study is aimed to determine the prevalence of
HIV and associated factors among VL infected patients
in the endemic areas of Northwest Ethiopia. The find-
ings of this study could be useful evidence for scholars
who are interested in the field and the ART programs




Facility based cross-sectional study design was employed
to assess the prevalence of HIV and associated factors
among VL patients who visited the health facilities in
Northwest Ethiopia.
Study settings and population
From the VL treatment centers found in the Northwest
Ethiopia, three hospitals and one health center were
selected purposely considering the availability of invasive
VL diagnostic methods such as demonstration of para-
site from spleen/lymph node aspiration or positive ser-
ology test if the patient has no VL history. In addition to
VL diagnostic method, we also considered the availabil-
ity of Fluorescence Activate Cell Sorting (FACS) count
machine for CD4 count and CBC (complete blood
count) machine. Hospitals and Health centers found in
the study area that fulfilled the above considerations
were considered as clusters (units). The selected
Hospitals and Health center are the only health facil-
ities that have well organized VL diagnosis and treat-
ment centers found in the study area. The excluded
health facilities in our study have not yet started diag-
nosing and treating VL patients. If VL patients visited
these health facilities then they will be referred to one
of the selected health facilities.
The study was carried out at four different sites in
Northwest Ethiopia. The first site was Abdrafi inpatient
kala-azar treatment center located in Abdrafi; at this
health center medical services are provided for patients
with Leishmaniasis, HIV-VL coinfection and snake bite.
The second site was kala-azar treatment and research
center in the University of Gondar Hospital located in
Gondar; at this center both outpatient and inpatient med-
ical services are provided for patients with Leishmaniasis
and HIV-VL coinfection in addition to the comprehensive
medical service from other units of the University of
Gondar Hospital. The third site was Kahsay Aberra
Hospital located in Humera kala-azar treatment center;
at this center both outpatient and inpatient medical
services are provided for patients with Leishmaniasis,
HIV-VL coinfection and many other hospital level ser-
vices. The fourth site was Metema Hospital located in
Metema kala-azar treatment center; at this center both
outpatient and inpatient medical services are provided
for patients with Leishmaniasis, HIV-VL coinfection
and many other hospital level services.
The sample size (n) was computed by single popula-
tion proportion formula n = [(zα/2) 2 × P (1-P)]/d2 by
assuming 95% confidence level of Zα/2 = 1.96, margin of
error 5% and we have taken proportion of 18.1% HIV-
VL coinfection conducted in endemic area of Amahara
region [10]. By considering this; the calculated sample
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size was 226.8 with adjustments for design effect of 2
and for non response rate (10%) the final sample size
became 500. The included study participants were 155,
79, 89 and 139 patients at Abdrafi health center, Metema
hospital, Humera hospital and University of Gondar
hospital respectively.
The study population was all VL patients who visited
VL treatment facilities found in Northwest Ethiopia.
Cluster sampling technique was employed to include
study participants. Therefore, Abdrafi Health center,
Metema Hospital, Humera Hospital, and University of
Gondar Hospital were the four selected clusters. All VL
diagnosed patients who visited and admitted to these
facilities were included in the study. In addition to this,
we have included HIV-VL coinfected patients who
already started receiving ART and VL patients who are
already started VL treatment during the beginning of the
study. All the included study participants were admitted
to the selected VL treatment centers and their admission
was because of their VL infections and not for other dis-
ease. Participants who were mentally incompetent and
unable to speak to undertook consent and interviews
were excluded from the study. The study period was
from October 7/2015 to August 5/2016.
Measurements
Diagnosis of VL was conducted according to the guide-
lines for the diagnosis of Leishmaniasis in Ethiopia [17].
The WHO case definition of VL was used as a starting
point; history of fever for more than 2 weeks, malaria
excluded, in combination with wasting and either
splenomegaly or lymphadenophaty [18]. A patient whose
illness met this case definition and who had no previous
VL treatment was diagnosed serologically by positive
rK39 rapid diagnostic test (Diamed-IT-Leish, DiaMed
AG) [19]. Patients with previous VL history underwent
splenic or lymph node aspiration and VL confirmed
parasitologically. A severely ill patient with a negative
rK39 test was aspirated without delay, so that a diagnosis
could be made as quickly as possible.
The selected health facilities have got both parasito-
logical and serological (rk39 dipstick test) VL diagnosis
methods. The standard means of parasitological diagno-
sis in VL entails microscopy and/or culture from spleen,
bone marrow or lymph node. While highly accurate, the
procedure is invasive, painful, and carries the risk of po-
tentially fatal bleeding. In order to avoid such problems
and taking into account the patient have no previous VL
infection we used serological tests for 46.32% of the in-
cluded study participants. But if the patient has previous
history of VL infection then the serological tests were
less effective. Hence, we have used parasitological tests
for 53.68% of the included study participants. VL diag-
nosis was made by laboratory technologists working in
the selected health facilities. After spleen or bone mar-
row aspirations were made as appropriate, laboratory
technologists and/or senior clinicians read the aspirates
at least twice. Wright or Giemsa staining was used as
available in the health facilities.
Provider-initiated testing and counseling for HIV was
offered to all VL patients. The HIV diagnosis was based
on the national algorithm with two serial positive rapid
test results; The KHB (Shanghi Kehua Bio-engineering,
ltd, 2008, China) HIV test was used to diagnose HIV.
For positive results, confirmation were done using STAT-
PAK test (chembio diagnostic system Inc, 2008, USA). In
case of discrepancy between the two tests, Uni-Gold™
(Trinity Biotech PLC, Bray, Ireland) was used as a tie
breaker. As VL is considered a stage IV-defining illness in
HIV patients [18, 20], all patients were given ART as soon
as they were stabilized from their acute illnesses. ART regi-
mens follow the national guidelines: tenofovir-lamivudine-
efavirenz; zidovudine-lamivudine-efavirenz; or zidovudine-
lamivudine-nevirapine [21] Second-line ART consists of
protease inhibitor-based combination regimens.
The clinical and treatment related data’s were ex-
tracted from the chart of each patient by using checklist.
Data on demographic factors were collected by using
structured and pretested questionnaire which was devel-
oped by the investigators. The structured questionnaire
was prepared in English version and translated into
Amharic (local language) and again back to English to
confirm the correctness of the translation. The data col-
lectors were 4 nurses and 4 laboratory technologist. We
employed four physicians and health officers as the su-
pervisors of the data collectors. One day training was
given to the data collectors and supervisors on the data
collection tool and sampling techniques. Supervision
was held regularly during data collection period. The
collected data was reviewed and checked for complete-
ness and relevance in each day before going to the next
day data collection.
Definition of variables
The dependent variable was HIV-VL coinfection and in-
dependent variables were socio-demographic variables,
clinical characteristics and treatment related variables.
The variables were defined as categorical variables with
the following:
HIV-VL coinfection – A person who was positive for
both VL and HIV diagnosis.
Spleen size - Spleen size of 15 cm and above is defined
as a huge splenomegaly, and is associated with
infarction, anemia and dragging abdominal pain.
Altitude adjusted hemoglobin: − the adjustment is
subtracted from each individual’s observed hemoglobin
level to calculate adjusted hemoglobin. The altitude of
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Gondar from sea level which is found to be 2,133 m
which will be adjusted by subtracting 0.8 g/dl from the
observed hemoglobin. The other places have an altitude
of less than 1000 m and there is no adjustment. [22].
Data analysis
Each completed questionnaire for socio-demographic,
clinical and treatment related variables was checked
visually for completeness before fed to the computer.
The data was entered into Excel, data cleanup and
cross-checking was done and it was analyzed by using
SPSS version 20. Descriptive statistics like frequencies
and cross tabulation was performed. All variables with
P-value <0.2 in bivariate analysis were included into a
multivariate step wise backward logistic regression
model. Goodness of fit for model was checked by Hosmer
and Lemeshow test. Hence, the assumption fitted the test
at P-value = 0.78 > 0.05. Crude and adjusted odds ratios
with 95% confidence interval was used to determine
the strength of association between dependent and in-
dependent variables. Variables having P-value ≤ 0.05
was considered as significant.
Results
A total of 462 study participants were included in the
study with response rate of 92.4%. The mean age (±SD)
of the included study participants was 26.47 (±9.19)
years. Ninety six point five percent (96.5%) of the study
participants were males. Majority of the respondents
95.24% were Orthodox Christians and 4.55% were
Muslim in religion. Almost half of the study participants
(49.80%) were unable to read and write. Three hundred
thirteen (67.75%) were reported single. Two hundred
twenty one (47.84%) of the included study participants
were farmers. Among the study participants 230
(49.78%) were urban residents (Table 1).
Eighty two (17.75 with 95% CI; 14.30–21.40) of the in-
cluded study participants were found to be HIV-VL
coinfected patients. Among the HIV-VL coinfected pa-
tients 54 (65.85%) were found to have a CD4 count less
than 100 cells/mm3. During diagnosis of VL the mean (±
SD) observed hemoglobin was 8.54 mg/dl (±2.15) and
216 (46.75%) of the study participants had hemoglobin
less than 8.5 mg/dl. After we adjusted for the altitude,
the mean (± SD) altitude adjusted hemoglobin was
8.29 mg/dl (±2.14) and 226 (48.92%) of the study partici-
pants had hemoglobin less than 8.29 mg/dl. During diag-
nosis of VL 346 (74.89%) of the study participants had a
spleen size less than 15 cm (Table 1). Thirty two
(39.02%) of the coinfected patients were newly diagnosed
for HIV-VL concurrent infection. Hence, they were not
started antiretroviral treatment (Table 1).
In the bivariate analysis residence, marital status, em-
ployment and age of the participant were significantly
associated with HIV-VL coinfection (Table 2).
The multivariate analysis was used to identify factors
that were predictive of HIV-VL coinfection. Age, resi-
dence and employment were independently associated
with HIV-VL coinfection (Table 3).
Discussions
This study focused on determining the prevalence of
HIV and associated factors among VL infected patients.
As a result, the prevalence was 17.75% and factors such
as age, residence and employment were associated with
HIV-VL coinfection. This is in line with other studies
which reported socio-demographic factors might have
an effect on HIV-VL coinfection [5, 10]. In addition to
this, there are few emerging articles which recommend
detailed studies on HIV-VL coinfection [23, 24].
As to this study result, the prevalence of HIV-VL coin-
fection was found to be 17.75%. This finding is almost
equal with the study conducted in Amhara region and
Humera Northwest Ethiopia which showed that the pro-
portion of HIV-VL coinfection was 18.1 and 18.6%
respectively [10, 25]. But this finding is lower than other
studies done in Ethiopia by using similar method, Army
Hospital, Addis Ababa from 1992 to 2001; Humera,
Northwest Ethiopia from 1998 to 2000; Humera,
Northwest Ethiopia, 2004; Gondar University Hospital,
Northwest Ethiopia from 1999 to 2004; Gondar University
and Humera Hospital, Northwest Ethiopia, from 2006 to
2008 in which HIV-VL coinfection was 48.5, 23, 28.5, 41
and 38.2% respectively [16, 26–29]. This might be due to
the effectiveness of national strategy on interventions of
behavioral change to reduce vulnerability to HIV in-
fection designed by government and non government
organizations. The other reason might be due to
raised awareness on using interventions to prevent
VL infection such as using insecticide treated bed net
to prevent sandfly bites.
Age of the study participants was found to be sig-
nificantly associated with HIV-VL coinfection. The
study participants with age ≥ 30 years had 22.58 times
risk for HIV-VL coinfection than the participants with
age < 30 years. This was in line with the study done
in Gondar University Hospital which showed that VL
patients of age group > 20 years were more than 3
times risk to have HIV infection as compared to
those 20 years and below [16]. The age group distri-
bution in coinfected patients is slightly higher in our
study but the bottom line is HIV-VL coinfection
mainly strikes adults. This study also gives additional
evidence on the HIV-VL coinfection mainly risks the
productive age groups (age ≥ 30) and this will help to
identify the target group for intervention.
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Employment of the participants was positively associ-
ated with HIV-VL coinfection in which those who were
daily laborers had 4.99 times risk for HIV-VL coinfection
than farmers. In addition to this, other professionals
such as government employees, non government em-
ployees, housewives and merchants together had 3.74
times risk for HIV-VL coinfection as compared to
farmers. The possible explanation for the first one is
daily laborers were mobile seasonal/migrant workers
who came from highlands to VL endemic lowland areas
for economical reason. Therefore, daily laborers are
likely to have no pre-existing immunity to VL and/or
lack of awareness about VL prevention methods as com-
pared to farmers who were resided in the lowlands. The
possible explanation of VL coinfection for the later is
farmers were benefitted from the massive scale-up of
insecticide treated nets for malaria control launched by
Ministry of Health in 2005 that may therefore have
collateral benefit for VL control [30]. The other reason
might be due to effectiveness of health extension
workers on interventions of behavioral change to reduce
vulnerability of HIV and VL infection of farmers [31].
Residence of the study participants was found to be
associated with HIV-VL coinfection. Those who were
from urban residence had 2.2 times risk for HIV-VL
coinfection as compared to rural residents. This find-
ing is in line with the current national HIV/AIDS
progress report of Ethiopia such as urban residents
are more affected by HIV than rural residents [8].
Table 1 Socio-demographic, clinical and treatment related





Age (years), mean (±SD) = 26.47 (±9.19)





≥ 51 11 2.38
Religion













Not read and write 230 49.80
Read and write 51 11.00







Daily laborer 138 29.87
Government employed 8 1.73
Non government employed 15 3.25
Merchant 74 16.02
Housewife 6 1.29
CD4+ count (mg/dl), mean (114.41)
< 100 314 67.97
≥ 100 148 32.03
Table 1 Socio-demographic, clinical and treatment related
characteristics of the study participants in Northwest Ethiopia, 2016
(Continued)
Observed Hb, mean (±SD) = 8.54 (±2.15)
< 8.54 225 48.7
≥ 8.54 231 50.0
Adjusted Hb, mean (±SD) = 8.29 (±2.14)
< 8.29 220 47.6
≥ 8.29 236 51.1
Spleen size, mean (±SD) = 7.66 (±4.88)
< 15 346 74.9
≥ 15 35 7.6
Duration of ART for HIV-VL patients
Not started 32 39.02
< 12months 11 13.41
12–36 months 19 23.17
≥ 37 20 24.39
Duration of VL treatment
≤ 5 days 172 37.23
6–15 days 98 21.21
≥ 16 days 192 41.56
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The reason behind the VL coinfection might be those
urban residents had a travel history to endemic areas for
different reasons such as to work as a daily laborer or for
other reason like trading purpose. Therefore, they might
have no pre-existing immunity to VL and/or lack of
awareness of VL prevention mechanism as compared to
farmers who permanently resided in low land areas.
In our study, CD4 cell count, Hb, and spleen size of
included patients did not significantly associated with
HIV-VL coinfection but this may be because of the small
sample size of the study and majority of the study partic-
ipants were male (97%). This is therefore makes unlikely
to obtain a significant association of the HIV prevalence
in this population since females are twice affected than
male population with HIV in Ethiopia [8]. Indeed, one
study has shown that CD4 cell count is important pre-
dictor of HIV-VL coinfection [15].
The findings of this study should be interpreted with
some limitations. The study relies on participants who
manage to come to the health institutions. We might not
get HIV-VL coinfected patients who couldn’t visit the
health facilities for different reason. Therefore, the esti-
mated prevalence may not exactly show the HIV-VL coin-
fection burden in the community. Moreover, self report of
historical VL events of the study participants were used
during VL diagnosis. Hence, recall bias could have
present. Majority of the study participants were male sex
and a little younger age groups; these may introduce some
bias to our study. The reason for not including more
female sex and older age groups were HIV-VL coinfected
Table 2 Bivariate associations of the levels of HIV-VL coinfection
with socio-demographic and clinical factors among VL infected
patients in Northwest Ethiopia, 2016
Characteristics of the
study participants
HIV-VL Coinfection COR (95% CI) P-value
Yes No
Sex 0.579
Male 80 366 1.53 (0.34, 6.87)
Female 2 14 r
Age 0.001
< 30 19 303 r
≥ 30 63 77 13.05 (7.37, 23.09)
Residence 0.001
Urban 60 170 3.37 (1.99, 5.72)
Rural 22 210 r
Marital status 0.001
Single 35 278 r
Married 20 77 2.06 (1.13, 3.78)
Divorced 27 25 8.58 (4.49, 16.39)
Employment 0.010
Farmer 28 193 r
Daily laborer 35 103 2.34 (1.35, 4.07)
Othersa 19 84 1.56 (0.83, 3.95)
Education 0.124
Not read and write 41 189 1.24 (0.73, 2.10)
Read and write 14 37 2.16 (1.03, 4.52)
First cycle and above 27 154 r
Observed Hb 0.385
< 8.54 43 182 1.24 (0.76, 2.01)
≥ 8.54 37 194 r
Altitude adjusted Hb 0.554
< 8.29 41 179 1.16 (0.71, 1.88)
≥ 8.29 39 197 r
Spleen size (cm) 0.304
< 15 64 282 r
≥ 15 4 31 0.57 (0.19, 1.67)
CD4+ count (mg/dl) 0.651
< 100 54 260 r
≥ 100 28 120 1.12 (0.66, 1.92)
r reference, agovernment employed, non government employed, housewife
and merchant, the stated P-values are the overall P-values. Pearson Chi-square
test was used to generate the P-values
Table 3 Multivariate association of the levels of HIV-VL coinfection
with factors among VL infected patients in Northwest Ethiopia, 2016
Variables HIV-VL
coinfection
COR (95% CI) AOR (95% CI) P-value
Yes No
Age
< 30 19 303 r r P = 0.001
≥ 30 63 77 13.05 (7.37, 23.09) 22.58 (11.34, 45.01)
Residence
Urban 60 170 3.37 (1.99, 5.72) 2.20 (1.16, 4.17) P = 0.016
Rural 22 210 r r
Marital status
Single 35 278 r
Married 20 77 2.06 (1.13, 3.78)
Divorced 27 25 8.58 (4.49, 16.39)
Employment
Farmer 28 193 r r P = 001
Daily laborer
35 103 2.34 (1.35, 4.07) 4.99 (2.33, 10.68)




41 189 1.24 (0.73, 2.10)
Read and
write




r reference, agovernment employed, non government employed,
housewife and merchant; the stated P-values are the overall P-values
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female and older age group patients were not found at all
the health centers during the study period.
Conclusion
HIV-VL coinfection in the Northwest Ethiopia was
found to be low. Age, residence and employment were
independently associated with HIV-VL coinfection in
the Northwest Ethiopia. It is better to design interven-
tions to prevent and control HIV-VL coinfection for
productive age groups (age ≥ 30) and daily laborers.
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